Accepted for Publication: August 31, 2021.
Published Online: January 20, 2022. doi:10.1001/jamaoncol.2021.7148
Corresponding Author: Murad Alam, MD, MSCI, MBA, Feinberg School of Medicine, Northwestern University, 676 N St Clair St, Ste 1600, Chicago, IL 60611 (firstname.lastname@example.org).
Author Contributions: Drs Kibbi and Alam had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Kibbi, Owen, and Worley contributed equally to this manuscript and are co–first authors. Dr Alam was the Guidelines Chair. Drs Kibbi, Owen, and Worley contributed equally to the drafting and revision of the manuscript.
Concept and design: Kibbi, Owen, Worley, Aung, Barker, Cartee, Choi, Chung, Dorigo, Fujisawa, Halfdanarson, Kanitakis, Khan, Lawrence, Maher, Ross, Solomon, Tolia, Arai, Brackett, Poon, Alam.
Acquisition, analysis, or interpretation of data: Kibbi, Owen, Worley, Wang, Harikumar, Downing, Aasi, Bolotin, Bordeaux, Chandra, Cho, Cliby, Dorigo, Eisen, Fujisawa, Golda, Halfdanarson, Iavazzo, Jiang, Kim, Kuzel, Leitao, MacLean, Maher, Mittal, Nehal, Ozog, Pettaway, Ross, Rossi, Servaes, Thomas, Voelzke, Waldman, Wong, Zhou, Brackett, Ibrahim, Kang, Poon, Alam.
Drafting of the manuscript: Kibbi, Owen, Worley, Wang, Fujisawa, Halfdanarson, MacLean, Ross, Solomon, Wong, Arai, Brackett, Kang, Alam.
Critical revision of the manuscript for important intellectual content: Kibbi, Owen, Worley, Harikumar, Downing, Aasi, Aung, Barker, Bolotin, Bordeaux, Cartee, Chandra, Cho, Choi, Chung, Cliby, Dorigo, Eisen, Golda, Halfdanarson, Iavazzo, Jiang, Kanitakis, Khan, Kim, Kuzel, Lawrence, Leitao, MacLean, Maher, Mittal, Nehal, Ozog, Pettaway, Ross, Rossi, Servaes, Solomon, Thomas, Tolia, Voelzke, Waldman, Wong, Zhou, Arai, Ibrahim, Kang, Poon, Alam.
Statistical analysis: Kibbi, Owen, Worley, Harikumar, Wong.
Obtained funding: Alam.
Administrative, technical, or material support: Kibbi, Worley, Fujisawa, Iavazzo, Ozog, Pettaway, Rossi, Solomon, Wong, Brackett, Ibrahim, Kang, Poon.
Supervision: Barker, Bolotin, Bordeaux, Cartee, Cliby, Eisen, Jiang, Kim, Kuzel, Lawrence, Nehal, Pettaway, Thomas, Voelzke, Arai, Alam.
Conflict of Interest Disclosures: Dr Worley reported serving as an advisory board member for Castle Biosciences outside of the submitted work. Dr Barker reported receiving grants from the National Institutes of Health through subcontracts from Physical Sciences Incorporated, EMD Serono, Alpha Tau Medical, Merck, and Amgen; personal fees from the American Society for Radiation Oncology, the American Brachytherapy Society, and Regeneron; and nonfinancial support from Alpha Tau Medical, H. Lee Moffitt Cancer Center, and Regeneron outside the submitted work. Dr Bolotin reported serving as an investigator without compensation on clinical trials for Replimune and Pelle Pharm outside the submitted work. Dr Chandra reported serving as an advisory board member for Exicure, Novartis, Bristol Myers Squibb, Sanofi Genzyme, and Regeneron outside the submitted work. Dr Choi reported receiving personal fees from Regeneron, Parexel, OnQuality Pharmaceuticals, Bristol Myers Squibb, and Kyowa Kirin International outside the submitted work. Dr Halfdanarson reported receiving personal fees from Curium, Lexicon, Terumo, and ScioScientific; receiving research support paid to the institution from Thermo Fisher Scientific, Basilea, Turnstone Biologics, Agios, and Novartis; and serving as a consultant with fees paid to the institution for ITM, Ipsen, and Novartis outside the submitted work. Dr Leitao reported receiving funding in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748; serving on the advisory board for and receiving personal fees from Ethicon/J&J and Takeda; and receiving grants to the institution from KCI/Acelity outside the submitted work. Dr Ross reported being an employee of Foundation Medicine Inc, being an equity owner in Roche Holdings, serving on the board of directors of and being an equity owner in Celsius Therapeutics Inc, and serving as a consultant to and being equity owner of Tango Therapeutics Inc. Dr Rossi reported serving as a consultant for Almirall, Merz, Dynamed, Canfield Scientific, Evolus, Biofrontera, Quantia MD, Lam Therapeutics, Regeneron, and Cutera; receiving travel support from Mavig and L’Oreal; serving on the advisory board for Allergan Inc and Skinfix; being founder of DAR Companies; receiving research grants from ASLMS: A Ward Memorial Research Grant and Skin Cancer Foundation; receiving research/study funding from Regen, LeoPharma, and Biofrontera; serving on the editorial boards of Lasers in Surgery and Medicine, Cutis, Journal of the American Academy of Dermatology, and Dermatologic Surgery; being a board member of ASDS; and being a committee member and/or chair for AAD, ASDS, and ASLMS. Dr Thomas reported serving as an advisory board committee member for Regeneron and Merck outside the submitted work. Dr Wong reported serving on the advisory board for Merck Pharmaceuticals, Bristol Myers Squibb, EMD Serona, Pfizer, Regeneron, and Castle Biosciences outside the submitted work. No other disclosures were reported.
Funding/Support: This article was partially supported by unrestricted research funding from the Section of Cutaneous Surgery in the Northwestern University Department of Dermatology. This research was funded, in part, by National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748 (to Dr Leitao).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Nobuo Arai, a patient representative who contributed his perspective based on personal experiences with extramammary Paget disease and helped shape the summary statements.
Chung PH, Kampp JT, Voelzke BB. Patients’ experiences with extramammary Paget disease: an online pilot study querying a patient support group. Urology
. 2018;111:214-219. doi:10.1016/j.urology.2017.08.045Crossref
Stenson A, Behjatnia B, Shamonki J, et al. Her2neu over-expression and PI3kinase/Akt pathway activation in Paget’s disease of the vulva. Reprod Sci. 2008;15(2):307A.
S , Thiede
R , Sadowsky
et al. Sex differences in initial treatment for genital extramammary Paget’s disease in the United States: a systematic review. J Am Acad Dermatol
. Published online April 20, 2019. doi:10.1016/j.jaad.2019.04.046
AM , Shelekhova
KV , Stewart
et al. Depth and patterns of adnexal involvement in primary extramammary (anogenital) Paget disease: a study of 178 lesions from 146 patients. Am J Dermatopathol
. 2016;38(11):802-808. doi:10.1097/DAD.0000000000000552
Z , Zhang
Q , Zhang
et al. Clinical and pathological characteristics of extramammary Paget’s disease: report of 246 Chinese male patients. Int J Clin Exp Pathol
. 2015;8(10):13233-13240.PubMedGoogle Scholar
YD , Cho
NH , Park
YS , Cho
SH , Lee
G , Park
K . Lymphovascular and marginal invasion as useful prognostic indicators and the role of c-erbB-2 in patients with male extramammary Paget’s disease: a study of 31 patients. J Urol
. 2005;174(2):561-565. doi:10.1097/01.ju.0000165148.16655.7c
SC , Marquez
CD , Porteus
C , Jiang
K . Anal canal adenocarcinoma with associated perianal Paget’s disease: an underrecognized entity with institutional experience. Lab Invest
. 2017;97(suppl 1):203A. doi:10.1038/labinvest.2016.168Google ScholarCrossref
R , Sasajima
Y , Tsuda
et al. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol
. 2013;168(6):1259-1266. doi:10.1111/bjd.12249
T , Ohtsuki
Y , Maeda
T , Furihata
M . Immunohistochemical and fluorescence in situ hybridization studies on noninvasive and invasive extramammary Paget’s disease. Int J Surg Pathol
. 2012;20(5):441-448. doi:10.1177/1066896912444159
H , Kitamura
S , Inamura
et al. mTOR expression correlates with invasiveness and progression of extramammary Paget’s disease. J Eur Acad Dermatol Venereol
. 2016;30(7):1238-1239. doi:10.1111/jdv.13168
S , Kilts
T , Schoolmeester
et al. HER2 amplification status in extramammary Paget disease (EMPD) evaluated by IHC, FISH and chromosomal microarray: review of 78 cases. Lab Invest
. 2019;99:2.Google Scholar
D , Dai
H , Jin
M , Zhao
Y . Clinicopathologic characteristics of extramammary Paget’s disease of the scrotum associated with sweat gland adenocarcinoma—a clinical retrospective study. J Chin Med Assoc
. 2011;74(4):179-182. doi:10.1016/j.jcma.2011.01.040
Y , Tanese
K , Hirai
I , Amagai
M , Kawakami
Y , Funakoshi
T . Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease. Br J Dermatol
. 2019;181(3):535-543. doi:10.1111/bjd.17789
Y , Nakamura
Y , Kawachi
Y , Otsuka
F . Indocyanine green fluorescence–navigated sentinel node biopsy showed higher sensitivity than the radioisotope or blue dye method, which may help to reduce false-negative cases in skin cancer. J Surg Oncol
. 2012;106(1):41-45. doi:10.1002/jso.23045
T , Okamoto
H . Usefulness of sentinel node navigation surgery with near-infrared fluorescence navigation using indocyanine green in patients with extramammary Paget’s disease. J Ger Soc Dermatol
. 2013;7:104-105. doi:10.1111/ddg.12163Crossref
T , Honda
T , Egawa
et al. Three-dimensional evaluation of subclinical extension of extramammary Paget disease: visualization of the histological border and its comparison to the clinical border. Br J Dermatol
. 2017;177(1):229-237. doi:10.1111/bjd.15282
Y , Hirai
I , Ishii
M , Kawakami
Y , Tanese
K , Funakoshi
T . Efficacy and safety of weekly docetaxel regimen for advanced extramammary Paget’s disease: retrospective single institute analysis. Ann Oncol
. 2018;29(suppl 9):ix108. doi:10.1093/annonc/mdy439.010
K , Li
GX , Kong
et al. Chemokine receptors CXCR4 and CXCR7 are associated with tumor aggressiveness and prognosis in extramammary Paget disease. J Cancer
. 2017;8(13):2471-2477. doi:10.7150/jca.19127
AA , Terushkin
V , Zitelli
et al. Intraoperative immunostaining for cytokeratin-7 during Mohs micrographic surgery demonstrates low local recurrence rates in extramammary Paget’s disease. Dermatol Surg
. 2018;44(3):354-364. doi:10.1097/DSS.0000000000001355
KJ , Tuur
S , Corvette
D , Lupton
GP , Skelton
HG . Cytokeratin 7 staining in mammary and extramammary Paget’s disease. Mod Pathol
. 1997;10(11):1069-1074.PubMedGoogle Scholar
M , Koike
I , Wada
et al. Definitive radiation therapy for extramammary Paget’s disease. Anticancer Res
. 2012;32(8):3315-3320.PubMedGoogle Scholar
Tackenberg S, Gehrig A, Dummer R, Navarini AA. External beam radiotherapy of extramammary Paget disease. Cutis. 2015;95(2):109-112.
Carrozzo AM, Cipriani C, Donati P, Muscardin L, Sedda AF. Dermo beta brachytherapy with 188Re in extramammary Paget’s disease. G Ital Dermatol Venereol. 2014;149(1):115-121.
Yanagi T, Kato N, Yamane N, Osawa R. Radiotherapy for extramammary Paget’s disease: histopathological findings after radiotherapy. Clin Exp Dermatol
. 2007;32(5):506-508. doi:10.1111/j.1365-2230.2007.02425.xCrossref
Hata M, Koike I, Wada H, et al. Postoperative radiation therapy for extramammary Paget’s disease. Br J Dermatol
. 2015;172(4):1014-1020. doi:10.1111/bjd.13357Crossref
Cai Y, Sheng W, Xiang L, Wu X, Yang H. Primary extramammary Paget’s disease of the vulva: the clinicopathological features and treatment outcomes in a series of 43 patients. Gynecol Oncol
. 2013;129(2):412-416. doi:10.1016/j.ygyno.2013.02.029Crossref
Piura B, Rabinovich A, Dgani R. Extramammary Paget’s disease of the vulva: report of five cases and review of the literature. Eur J Gynaecol Oncol. 1999;20(2):98-101.
Kato M, Yoshino K, Maeda T, et al. Single-agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series. Br J Dermatol
. 2019;181(4):831-832. doi:10.1111/bjd.17922Crossref
Nakamura Y, Tanese K, Hirai I, et al. Weekly docetaxel monotherapy for metastatic extramammary Paget’s disease: retrospective single-institute analysis. J Dermatol
. 2020;47(4):418-422. doi:10.1111/1346-8138.15255Crossref
Tokuda Y, Arakura F, Uhara H. Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease. Int J Clin Oncol
. 2015;20(1):194-197. doi:10.1007/s10147-014-0686-2Crossref
Ishida Y, Iga N, Otsuka A, Kabashima K. Mutational landscape of extramammary Paget disease. J Invest Dermatol. 2018;138(5 suppl 1):S22.
Kiniwa Y, Yasuda J, Saito S, et al. Identification of genetic alterations in extramammary Paget disease using whole exome analysis. J Dermatol Sci
. 2019;94(1):229-235. doi:10.1016/j.jdermsci.2019.03.006Crossref
Gatalica Z, Vranic S, Krušlin B, et al. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget’s disease. Cancer Med
. 2020;9(4):1441-1450. doi:10.1002/cam4.2820Crossref
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol
. 2020;21(10):1353-1365. doi:10.1016/S1470-2045(20)30445-9Crossref
Karam A, Berek JS, Stenson A, Rao J, Dorigo O. HER-2/neu targeting for recurrent vulvar Paget’s disease: a case report and literature review. Gynecol Oncol
. 2008;111(3):568-571. doi:10.1016/j.ygyno.2007.12.014Crossref